K/B×N serum transfer arthritis is delayed and less severe in leukaemia inhibitory factor (LIF)-deficient mice

Clinical and Experimental Immunology

Volumn 169, Issue 2, 2012, Pages 71-78

  Upadhyay, A ^a   Senyschyn, D ^a   Santos, L ^b,g   Gu, R ^b   Carroll, G J ^c,d,e   Jazayeri, J A ^a,f  

^a MONASH UNIVERSITY   (Australia)

^b MONASH MEDICAL CENTRE   (Australia)

^c FREMANTLE HOSPITAL   (Australia)

^d UNIVERSITY OF NOTRE DAME   (Australia)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^f CHARLES STURT UNIVERSITY   (Australia)

^g UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

K B N serum; Leukaemia inhibitory factor; Mice arthritis model

Indexed keywords

GLYCOPROTEIN GP 130; INTERLEUKIN 1; INTERLEUKIN 6; LEUKEMIA INHIBITORY FACTOR; LEUKEMIA INHIBITORY FACTOR RECEPTOR; ONCOSTATIN M; ONCOSTATIN M RECEPTOR; RNA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE ATROPHY; BONE INJURY; CARTILAGE DEGENERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; FEMALE; GENE EXPRESSION; HETEROZYGOTE; HISTOPATHOLOGY; IMMUNOPATHOGENESIS; JOINT EFFUSION; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; POLYARTHRITIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; SCORING SYSTEM; SYNOVITIS;

ANIMALS; ARTHRITIS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; INTERLEUKIN-6; LEUKEMIA INHIBITORY FACTOR; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTORS, INTERLEUKIN-6;

EID: 84863572640     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2012.04601.x     Document Type: Article

References (28)

1. Lettesjo H, Nordstrom E, Strom H etal. Synovial fluid cytokines in patients with rheumatoid arthritis or other arthritic lesions. Scand J Immunol 1998; 48:286-92.
2. Feldmann M. Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol 2002; 2:364-71.
3. Kremer JM, Westhovens R, Leon M etal. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003; 349:1907-15.
4. Okamoto H, Yamamura M, Morita Y etal. The synovial expression and serum levels of interleukin-6, interleukin-11, leukemia inhibitory factor, and oncostatin M in rheumatoid arthritis. Arthritis Rheum 1997; 40:1096-105.
5. Arend WP. Cytokine imbalance in the pathogenesis of rheumatoid arthritis: the role of interleukin-1 receptor antagonist. Semin Arthritis Rheum 2001; 30 (Suppl 2):1-6.
6. Arend WP. Physiology of cytokine pathways in rheumatoid arthritis. Arthritis Rheum 2001; 45:101-6.
7. Lotz M, Moats T, Villiger PM. Leukemia inhibitory factor is expressed in cartilage and synovium and can contribute to the pathogenesis of arthritis. J Clin Invest 1992; 90:888-96.
8. Hui W, Bell M, Carroll G. Oncostatin M (OSM) stimulates resorption and inhibits synthesis of proteoglycan in porcine articular cartilage explants. Cytokine 1996; 8:495-500.
9. Bell MC, Carroll GJ. Rheumatoid synovial fluid contains bioactive leukemia inhibitory factor with cartilage degrading activity - another target for chondroprotective intervention. J Rheumatol 2000; 27:332-8.
10. Bell M, Carroll GJ, Chapman H etal. Leukemia inhibitory factor (LIF) binding protein attenuates the phlogistic and abolishes the chondral effects of LIF in goat joints. J Rheumatol 1997; 24:2394-402.
11. Carroll GJ, Bell MC, Chapman HM etal. Leukemia inhibitory factor induces leukocyte infiltration and cartilage proteoglycan degradation in goat joints. J Interferon Cytokine Res 1995; 15:567-73.
12. Banner LR, Patterson PH, Allchorne A etal. Leukemia inhibitory factor is an anti-inflammatory and analgesic cytokine. J Neurosci 1998; 18:5456-62.
13. Benigni F, Fantuzzi G, Sacco S etal. Six different cytokines that share GP130 as a receptor subunit, induce serum amyloid A and potentiate the induction of interleukin-6 and the activation of the hypothalamus-pituitary-adrenal axis by interleukin-1. Blood 1996; 87:1851-4.
14. Heymann D, Godard A, Raher S etal. Leukemia inhibitory factor (LIF) and oncastsin M (OSM) high affinity binding require additional receptor subunits besides GP130 and GP190. Cytokine 1996; 8:197-205.
15. Desgeorges A, Gabay C, Silacci P etal. Concentrations and origins of soluble interleukin 6 receptor-alpha in serum and synovial fluid. J Rheumatol 1997; 24:1510-6.
16. Morgan TG, Rowan AD, Dickinson SC etal. Human nasal cartilage responds to oncostatin M in combination with interleukin 1 or tumour necrosis factor alpha by the release of collagen fragments via collagenases. Ann Rheum Dis 2006; 65:184-90.
17. Monach P, Hattori K, Huang H etal. The K/BxN mouse model of inflammatory arthritis: theory and practice. Methods Mol Med 2007; 136:269-82.
18. Ditzel HJ. The K/BxN mouse: a model of human inflammatory arthritis. Trends Mol Med 2004; 10:40-5.
19. Bell MC, Carroll GJ, Chapman HM etal. The proinflammatory and chondral activities of leukemia inhibitory factor in goat joints are partially a function of interleukin-1. J Interferon Cytokine Res 1999; 19:197-208.
20. Varghese S, Yu K, Canalis E. Leukemia inhibitory factor and oncostatin M stimulate collagenase-3 expression in osteoblasts. Am J Physiol 1999; 276:E465-471.
21. Truett GE, Heeger P, Mynatt RL etal. Preparation of PCR-quality mouse genomic DNA with hot sodium hydroxide and tris (HotSHOT). Biotechniques 2000; 29:52-4.
22. Santos LL, Dacumos A, Yamana J etal. Reduced arthritis in MIF deficient mice is associated with reduced T cell activation: down-regulation of ERK MAP kinase phosphorylation. Clin Exp Immunol 2008; 152:372-80.
23. Fleming KK, Bovaird JA, Mosier MC etal. Statistical analysis of data from studies on experimental autoimmune encephalomyelitis. J Neuroimmunol 2005; 170:71-84.
24. Van de Loo FA, Arntz OJ, Van den Berg WB. Effect of interleukin 1 and leukaemia inhibitory factor on chondrocyte metabolism in articular cartilage from normal and interleukin-6-deficient mice: role of nitric oxide and IL-6 in the suppression of proteoglycan synthesis. Cytokine 1997; 9:453-62.
25. Alonzi T, Fattori E, Lazzaro D etal. Interleukin 6 is required for the development of collagen-induced arthritis. J Exp Med 1998; 187:461-8.
26. Sasai M, Saeki Y, Ohshima S etal. Delayed onset and reduced severity of collagen-induced arthritis in interleukin-6-deficient mice. Arthritis Rheum 1999; 42:1635-43.
27. Kyburz D, Carson DA, Corr M. The role of CD40 ligand and tumor necrosis factor alpha signaling in the transgenic K/BxN mouse model of rheumatoid arthritis. Arthritis Rheum 2000; 43:2571-7.
28. Zhu M, Oishi K, Lee SC etal. Studies using leukemia inhibitory factor (LIF) knockout mice and a LIF adenoviral vector demonstrate a key anti-inflammatory role for this cytokine in cutaneous inflammation. J Immunol 2001; 166:2049-54.